MP Materials Corp. reported Q1 2026 financial results, generating $132.9 million of revenue and PPA income for the quarter.

The company reported adjusted EBITDA of $36.6 million and adjusted diluted EPS of $0.03 per share for the quarter.

The Materials segment generated $114.5 million of revenue and PPA income along with $36.7 million of segment adjusted EBITDA. The Magnetics segment drove $21.1 million of revenue and $9.6 million of segment adjusted EBITDA in the quarter.

The company ended the quarter with $1.7 billion of cash and short-term investments.

During the quarter, the Materials segment produced a record 917 metric tons of NPR oxide and delivered just under 13,000 metric tons of REO concentrate.

Management noted they began initial shipments to a newest U.S. customer, driving total NDPR oxide sales of 1,006 metric tons.

The company recently broke ground on its 10x facility and is advancing the engineering design of the recycling circuit for its agreement with Apple.

The heavy rare earth separation circuit is expected to begin commissioning in the second quarter.

Looking ahead, management expects second quarter realized pricing to be in the low to mid-90s per kilogram.

The company expects to achieve a single-digit quarter-over-quarter decline in NDPR oxide production in the second quarter due to a maintenance outage, followed by significant sequential growth in the third quarter.

Full year capital expenditures are expected to be $500 million to $600 million.

Initial magnet revenue is expected in the second half of 2026.

MercadoLibre, Inc. reported its Q1 2026 financial results, highlighting "net revenue up 49% year-over-year" and delivering "$611 million of income from operations, representing a 6.9% margin". Management noted that the margin compression reflects a deliberate choice to invest in strategic initiatives, stating they are "not trying to optimize short-term margins".In commerce, Brazil was a standout market where "GMV grew 38% year-over-year as items sold growth accelerated to 56%". A key driver was the "decision to lower the free shipping threshold in Brazil" to BRL 19, which management called "a sustained growth engine across multiple quarters". Additionally, logistics efficiency improved, with "cost per shipment down 17% year-over-year in local currency". Other regions also saw solid growth, with GMV increasing 28% in Mexico, 41% in Argentina, and 40% in Chile.

The fintech segment saw significant expansion, as the company's "credit portfolio nearly doubled to $14.6 billion" and they issued "2.7 million credit cards this quarter". Management emphasized scaling the credit card in Mexico and Argentina while launching "private payroll loans" in Brazil. On the technology front, MercadoLibre "deployed LLMs in search in commerce for the first time this quarter" across Brazil, Mexico, and Argentina, which is "one piece in a much more broad Gen AI strategy for the marketplace". Regarding future expectations, management reiterated that they "rather not talk about margins on a quarterly basis and forward-looking".

Insmed Incorporated reported its first quarter 2026 financial results, noting that "cost of product revenues in the first quarter of 2026 was $47.4 million or 15.5% of revenues". Management highlighted its cash position, stating that as of the end of the first quarter of 2026, the company had approximately $1.2 billion in cash, cash equivalents and marketable securities.

Executives expressed confidence in the company's financial trajectory, stating they "would expect to achieve sustainable cash flow positivity in 2027" without requiring additional capital to support their existing business.

During the quarter, management stated that "BRINSUPRI's launch continues to exceed our expectations," delivering 44% sequential growth.

The company noted strong payer access, with an approval rate of nearly 90% for patients processed through specialty pharmacies since launch.

Additionally, more than 80% of patients on the therapy have enrolled in the inLighten patient support program.

Insmed also launched Suspect BE, a new diagnosis-focused disease education campaign aimed at raising awareness and proper diagnosis of bronchiectasis.In clinical updates, Insmed plans to submit data from the Phase 3b ENCORE study of ARIKAYCE to regulatory authorities in the U.S. and Japan in the second half of the year.

The company also advanced its TPIP pipeline, opening the first site for the Phase 3 PALM PAH study and anticipating data from a Phase 2b open-label extension study in the third quarter of this year.

Looking forward, the company reiterated its full year 2026 revenue guidance of "at least $1 billion" for BRINSUPRI.

Whirlpool Corporation reported first quarter 2026 results, noting "we delivered an ongoing EBIT margin of 1.3% and an ongoing earnings per share of negative $0.56" for the quarter.

First quarter free cash flow was negative $896 million. In the MDA North America segment, "net sales decreased 8% year-over-year to $2.2 billion" in the first quarter.

Conversely, the SDA global business performed well, "delivering approximately 10% net sales growth year-over-year" and an EBIT margin of 21%.

Management highlighted that "consumer sentiment has dropped to its lowest level in 50 years", driving U.S. appliance industry demand down 7.4% in the first quarter, with March down 10%. In response, executives announced "a promotional price increase, which is already in effect of more than 10% relative to the first quarter prices", alongside a lease price increase of "approximately 4%" effective July 9. The company reaffirmed a "commitment to deliver our $150 million in cost take out in 2026". Operational moves include a $60 million investment in a new production facility in Perrysburg, Ohio, modernization of the Amana, Iowa plant to generate an expected annualized EBIT benefit of approximately $70 million, and shifting front load washer production from Pilar, Argentina to Rio Claro, Brazil.

For the full year 2026, Whirlpool revised its expectations, forecasting "revenue growth of approximately 1.5%" on a like-for-like basis.

Full year guidance includes a "full year EBIT margin of approximately 4%" and "full year ongoing earnings per share of $3 to $3.50". The company expects to generate full year free cash flow of "more than $300 million". To ensure financial flexibility, management made the decision to "pause our quarterly dividend starting in the second quarter" to create capacity on the balance sheet to "pay down more than $900 million of debt in 2026".Product innovation remains a key priority with the introduction of the Artisan Plus stand mixer and a compact fully automatic espresso machine.

The company noted the successful national rollout of the Whirlpool branded UV laundry tower, which captures "approximately 5 points" of share within weeks.

Executives also showcased the new KitchenAid intelligent wall oven, which earned the Best of Show Award at KBIS, and the InSinkErator LEDefense Odor Fighting Sink Flange.

Albemarle Corporation reported "net sales of $1.4 billion, up 33% year-over-year" for the first quarter of 2026.

The company delivered adjusted EBITDA of $664 million for the quarter, reflecting higher pricing and volume in Energy Storage and Specialties.

First quarter net sales for Energy Storage increased 70% year-over-year, while the Specialties segment saw net sales increase 12% year-over-year.

The company reported diluted earnings of $2.34 per share for the quarter.

For the first quarter, the company generated $346 million of operating cash flow and $248 million of free cash flow.

During the first quarter, the company repaid $1.3 billion of debt following the successful sales of the Eurecat joint venture and a controlling stake in Ketjen.

Management noted they "ended the first quarter with a net debt-to-EBITDA leverage ratio of 1x". Albemarle achieved $40 million in cost and productivity improvements year-to-date.

Operations at Wodgina and Greenbushes are operating in line with expectations, and the CGP3 investment at Greenbushes is operational and ramping as planned. At the Salar de Atacama, the company has initiated the environmental permitting process for a commercial direct lithium extraction project, and the Kings Mountain project recently received federal mining permits.

For the full year 2026, Albemarle is raising its outlook for the Specialties segment, guiding for net sales between $1.3 billion and $1.5 billion, and an adjusted EBITDA outlook between $225 million and $275 million.

The company is maintaining its total company outlook for 2026 across all three price scenarios despite global supply chain disruptions related to the Middle East.

Management estimates that the unmitigated full year cost impact of these supply chain disruptions would be approximately $70 million to $90 million.

The company continues to expect full year capital expenditures of $550 million to $600 million and remains on track to hit its full year 2026 cost and productivity improvements target of $100 million to $150 million.

HubSpot, Inc. reported financial results for the first quarter of 2026, noting that "Q1 revenue grew 23% year-over-year as reported and 18% in constant currency." For the first quarter, "Non-GAAP operating margin was 18%", and "GAAP operating margin was 3% in Q1." Management stated "Non-GAAP net income was $143 million, and non-GAAP net income per diluted share was $2.72" for the first quarter.

Additionally, "in the first quarter, the company generated $154 million of free cash flow or 17% of revenue."Management highlighted strong customer growth, noting that "total customer count reached nearly 300,000 globally, driven by 10,800 net customer additions in the quarter." Executive Yamini Rangan shared upmarket momentum figures for the quarter, stating that "deals over 60,000 annual recurring revenue grew 37% year-over-year and deals over 120,000 ARR grew 64% year-over-year." Regarding AI adoption, Rangan stated that "Active core seat users grew 90% year-over-year" and "Total credits consumed grew 67% quarter-over-quarter." Management also shared that "Nearly 14,000 customers have activated" the Prospecting Agent and "Over 9,000 customers have activated data agent."The company announced packaging and pricing shifts, "moving to outcome-based pricing for customer and prospecting agents and introducing 28-day free trials for our agents and HubSpot AEO." On the corporate and product front, the company noted it "launched HubSpot AEO at Spring spotlight" to help marketers see how their brand appears in AI tools, and highlighted inorganic demand generation investments, having "bought 2 incremental acquisitions in Q1, starter story and future PDS."Looking ahead, CFO Kathryn Bueker provided forward guidance for the second quarter of 2026, stating "total as reported revenue is expected to be in the range of $897 million to $898 million", with "Non-GAAP operating income is expected to be between $173 million and $174 million" for the second quarter.

For the full year of 2026, "total as reported revenue is now expected to be in the range of $3.7 billion to $3.708 billion", and "Non-GAAP operating income is now expected to be in the range of $762 million to $766 million."

Vistra Corp. reported first quarter 2026 results, delivering $1.494 billion in adjusted EBITDA for the first quarter of 2026.

Generation delivered $1.426 billion of adjusted EBITDA in the quarter, while Retail delivered $68 million of adjusted EBITDA. The company deployed approximately $525 million in share repurchases during the first 4 months of the year and paid a first quarter dividend of approximately $75 million.

Management highlighted a structurally improved demand environment, noting the announced acquisition of the 5,500-megawatt Cogentrix natural gas generation portfolio.

The company also announced long-term power purchase agreements with Meta for approximately 2,600 megawatts of energy and capacity at its PJM nuclear sites.

Vistra currently has approximately 4,500 megawatts of organic development opportunities recently completed or in process across its portfolio.

The company also received an upgrade of its corporate issuer rating to investment grade from Fitch Ratings, which triggered fallaway provisions to release the liens on its assets.

Looking ahead, Vistra is reaffirming the guidance ranges for 2026 adjusted EBITDA and adjusted free cash flow before growth, and maintaining its 2027 adjusted EBITDA midpoint opportunity range.

Management noted it still has line of sight to more than $10 billion of cash generation over 2026 and 2027.

Vistra plans to allocate approximately $3 billion to equity holders and approximately $4 billion toward accretive growth investments, leaving approximately $3 billion of additional capital available to allocate through year-end 2

For the first three months of 2026, Novo Nordisk A/S announced that "reported sales increased by 32%, reaching DKK 96.8 billion" for the quarter.

However, adjusted sales declined by 4%, driven by lower realized prices, which was partly offset by GLP-1 volume growth and market expansion.

The adjusted gross margin decreased to 80.6% compared to 83.5% in 2025, and adjusted operating profit decreased by 6% at CER. The company invested about DKK 22 billion in research and development and commercial initiatives during the first quarter of 2026, while returning nearly DKK 38 billion to shareholders through dividends and share buybacks.

Management noted that obesity care sales increased 22%, driven by both operating units, with international operations growing by 44% and U.S. operations growing by 9%.

The Wegovy Pill launched in the United States and has seen over 1 million people using the treatment, generating more than 2 million total prescriptions since launch.

Executives stated the company is focused on driving competitiveness, progressing the pipeline, and making focused investments towards growth opportunities.

The company is also utilizing TeleHealth partnerships, which account for around 20% of sales in some of their largest markets.

Forward guidance for 2026 was raised, with adjusted sales growth now expected to be between minus 4% and minus 12%.

Adjusted operating profit growth for 2026 is expected to be minus 4% to minus 12% at CER. Management stated this improvement in the outlook is mainly driven by increased expectations for GLP-1 product sales.In terms of product and partnership announcements, the company received FDA approval for high-dose semaglutide at 7.2 milligrams in the U.S. and initiated two pivotal Phase III trials in the cenogamtide development program, AMAZE. In the first quarter of 2026, the company achieved 6 regulatory approvals and more than 10 clinical trial initiations.

Aweekly received FDA approval as a once-weekly long-acting basal insulin for people living with type 2 diabetes.

Executives also highlighted building partnerships, such as a collaboration with OpenAI, to help ensure strong positioning for the future.

Natera reported first quarter 2026 financial results with "revenues of $697 million in Q1," which represented "39% growth over last year". The company achieved "gross margins coming in at just under 65%" for the quarter.

Management noted that the "rapid increase in volumes in Q1 actually harmed margins by roughly 2 percentage points because we had more samples in process in the lab at the close of the quarter than normal".Management highlighted a milestone of "delivering 1 million units in a single quarter". The oncology division "processed 249,000 clinical oncology units in the quarter," representing a record increase.

The company also saw a successful launch of its "fetal focused product," which is "approaching a run rate of nearly 200,000 focus orders". Additionally, the company is seeing success from its "integration with Onco EMR" and the acquisition of Foresight Diagnostics, leveraging "phased variant technology" to drive biopharma interest.

For forward guidance, Natera announced it will "fully reset the revenue guide range by more than $120 million and increase our gross margin guidance to 65% at the midpoint". Management also plans to "bump R&D expectations by $50 million, primarily to pull forward" clinical trials.

Notable updates included positive interim data from the ALPHA3 trial sponsored by Allogene Therapeutics, the progression of the FIND CRC screening study, and preparations for a broad commercial launch of Signatera in Japan with PMDA approval remaining "on track for Q2 2026".TWEETNatera $NTRA reported Q1 2026 earnings: 📊 Revenue: $697 million (Q), 39% growth ✅ Momentum: "integration with Onco EMR" & "record growth quarter for oncology" 🐂 Bull: "gross margins coming in at just under 65%" 🐻 Bear: "we had more samples in process in the lab" 🎧 Listen: [LINK]

Ginkgo Bioworks Holdings, Inc. reported its first quarter 2026 financial results.

Revenue was $19 million in the first quarter of 2026, down 49 percent compared to the first quarter of 2025.

Adjusted EBITDA in the first quarter of 2026 was negative $42 million, and cash burn in the first quarter of 2026 was $48 million.

The company reported a cash position of $373 million with no bank debt as of the first quarter of 2026.

Management stated that the focus for 2026 will be investing to win the category of autonomous labs.

The company closed the spin-off of its biosecurity unit into a new company called Perimeter on April 3, and Ginkgo now operates as a single segment.

The company is actively scaling its Nebula autonomous lab in Boston, expanding from 50 to 105 racks by the end of the month, and successfully launched its Cloud Lab service to the public.

For forward guidance, management reaffirmed their overall cash burn guidance for 2026, totaling $125 million to $150 million.

Management highlighted three new channels coming to their service business, including Amazon Biodiscovery, Benchling, and Tamarind Bio.

The company also discussed a project with OpenAI using GPT 5 that demonstrated a 40 percent improvement in the cost of cell-free protein synthesis over scientific state-of-the-art.